Charles River Laboratories CRL Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's change in deferred revenue?
- Charles River Laboratories (CRL) reported change in deferred revenue of $5.2M in Q1 2026.
- How has Charles River Laboratories's change in deferred revenue changed year-over-year?
- Charles River Laboratories's change in deferred revenue increased by 528.4% year-over-year, from -$1.21M to $5.2M.
- What is the long-term trend for Charles River Laboratories's change in deferred revenue?
- Over 3 years (2021 to 2025), Charles River Laboratories's change in deferred revenue has grown at a 41.7% compound annual growth rate (CAGR), from -$13.4M to -$38.14M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.